|
Research Type
|
Pure and Applied Science / Translational |
|
Keywords
|
Spinal Cord Contusion Detrusor-sphincter dyssynergia detrusor overactivity |
|
Target Audience
|
Urology, Urogynaecology and Female & Functional Urology, Bowel Dysfunction, Pure and Applied Science |
|
Aims and Objectives
|
Spinal cord injury (SCI) causes impairment of mobility and neurogenic detrusor overactivity (NDO) that contribute to a decreased quality of life. This workshop will describe: i) the current state-of-the-art management of lower urinary tract (LUT) dysfunction associated with SCI; ii) the pathophysiology of this dysfunction; and iii) the therapeutic potential of three pharmacological agents to promote functional LUT recovery after SCI. These agents are: LM11A-31, a neurotrophin receptor modulator; LM22B-10, an agent that promotes neuronal growth; and cinaciguat, a soluble guanlyate cyclase activator that supports repair of spinal lesions. LM11A-31 and cinaciguat have passed human safety tests and may readily transition to clinical trials.
|